Cytek Biosciences (CTKB) awards 241,416 RSUs and 127,118 options to top lawyer
Cytek Biosciences (CTKB) has granted new equity awards to its Chief Legal Officer and Secretary, Ilan Feuchtwang. These awards include 241,416 Restricted Stock Units (RSUs) and an option to purchase 127,118 shares of common stock at an exercise price of $4.66 per share. Both the RSUs and options will vest over a four-year period, contingent upon Feuchtwang's continuous service to the company.
Cytek Biosciences: Recurring Revenue Reaches 35% Of Sales As Installed Base Approaches 4,000 Instruments
Cytek Biosciences is seeing its recurring revenue, from service and reagent sales, grow as it expands its global installed base of instruments and introduces new cell-analysis platforms. Recurring revenue now accounts for 35% of total sales on a trailing 12-month basis, up from 32% a year prior, while the installed base neared 4,000 instruments. The company also launched new products like Borealis and expanded Aurora Evo configurations, contributing to a 6% increase in Q2 revenue and a raised full-year revenue outlook.
Cytek Biosciences, Inc. (8EQ.MU) Analyst Insights, Price Targets & Recommendations
This article provides analyst insights, price targets, and recommendations for Cytek Biosciences, Inc. (8EQ.MU). It lists several recent analyst actions including upgrades, downgrades, and maintained ratings from firms like Piper Sandler, Goldman Sachs, Stephens & Co., and Morgan Stanley, along with the corresponding dates. The stock's current trading price is also displayed.
Cytek Biosciences (CTKB) holders report over 7% stakes in Schedule 13G/A
Millennium-affiliated entities and Israel A. Englander have filed an amended Schedule 13G/A, disclosing significant ownership stakes in Cytek Biosciences, Inc. Integrated Core Strategies (US) LLC reported a 5.5% beneficial ownership, while Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each reported 7.2% beneficial ownership, all with shared voting and dispositive power. The filing emphasizes that this structure does not, by itself, constitute an admission of beneficial ownership by the reporting persons.
Cytek Biosciences, Inc. 2Q 2026: Revenue $48.14M, EPS ($0.09) — 10-Q Summary
Cytek Biosciences, Inc. reported its second-quarter 2026 results, showing a 5.6% year-over-year revenue increase to $48.14 million, alongside a net loss of $12.16 million and diluted EPS of ($0.09). Revenue growth was fueled by product and service gains, with improved gross margin attributed to tariff refunds and lower service material costs. The company also expanded its direct and distributor sales channels and invested in R&D and global hiring.
Cytek Biosciences, Inc. (CTKB) Stock Price, News, Quote & History
This Yahoo Finance page provides a comprehensive overview of Cytek Biosciences, Inc. (CTKB), including its current stock price, recent news, historical data, and financial analysis. The company specializes in cell analysis solutions for biomedical research and clinical applications, offering various instruments and reagents. The article also details CTKB's earnings trends, analyst insights, valuation measures, and allows for comparison with similar medical device companies.
Cytek Biosciences Reports Second Quarter 2026 Financial Results
Cytek Biosciences reported its second-quarter 2026 financial results, with total revenue reaching $48.1 million, a 6% increase year-over-year. The company also announced the launch of new instruments, the Cytek Borealis™ and updated Cytek Aurora™ Evo configurations, and updated its full-year 2026 revenue guidance to $207 million to $212 million. Despite increased operating expenses and a net loss, the company highlighted strong instrument growth and recurring revenue expansion.
Cytek Biosciences Inc (CTKB) (Q2 2026) Earnings Call Highlights: Revenue Up 6% to $48. ...
Cytek Biosciences (CTKB) reported a 6% year-over-year revenue increase to $48.1 million in Q2 2026, driven by strong growth in the US and China, particularly from high-end instrument sales and services. Despite this, the company saw a widened GAAP net loss of $12.2 million and a negative Adjusted EBITDA, primarily due to increased operating expenses and softness in the EMEA region. Cytek raised its full-year revenue guidance to $207 million-$212 million and maintains a strong cash balance, with expectations for continued growth driven by new product launches like the Borealis and strategic reorganization.
Cytek Biosciences, Inc. - Common Stock (CTKB) Stock Price, News, Quote & History
This page provides detailed stock information for Cytek Biosciences, Inc. (CTKB), including its current price, trading data, and company overview. It also features a collection of recent news and press releases highlighting the company's financial results, new product launches, expansion efforts, and industry recognitions.
Cytek Biosciences Q2 Earnings Call Highlights
Cytek Biosciences reported a 6% year-over-year revenue increase to $48.1 million in Q2 2026, driven by strong growth in the U.S. and China, despite weakness in Europe and parts of Asia-Pacific. The company expanded its installed base to 3,933 instruments and saw recurring revenue grow by 8%. Despite a widening GAAP net loss, Cytek raised its full-year 2026 revenue outlook.
Cytek Biosciences Q2 GAAP net loss widens to $12.2 million; revenue rises 6% year over year to $48.1 million
Cytek Biosciences reported its Q2 2026 financial results, showing a 6% year-over-year increase in revenue to $48.1 million. Despite the revenue growth, the company's GAAP net loss widened to $12.2 million, and its GAAP operating loss increased to $11.4 million. The gross margin improved to 59%, and the company raised its full-year 2026 revenue guidance to between $207 million and $212 million.
Cytek Biosciences (CTKB) Releases Q2 2026 Earnings: Revenue Growth but EPS Miss
Cytek Biosciences (CTKB) reported Q2 2026 revenue of $48.1 million, a 5.6% increase year-over-year, and gross profit rose by 18.7% to $28.3 million. Despite revenue growth, the company posted a net loss of $12.2 million, or $(0.09) diluted EPS, missing analyst expectations of $(0.0867) EPS and $49.6 million in revenue. The article also details hedge fund activity, government contracts, and analyst price targets for CTKB.
Cytek Q2 2026 Earnings: Revenue Rose 6% as Losses Widened
Cytek (Nasdaq: CTKB) reported a 6% increase in Q2 2026 revenue to $48.1 million, driven by instrument growth in the U.S. and China and higher service revenue. However, the company's net losses widened significantly due to a faster increase in operating expenses and weaker non-operating results. A one-time tariff refund boosted reported gross margin, but excluding this, the underlying margin was flat, while adjusted EBITDA turned negative, highlighting ongoing profitability challenges.
Earnings call transcript: Cytek Biosciences posts q2 2026 revenue growth, shares fall
Cytek Biosciences reported a 6% increase in second-quarter 2026 revenue to $48.1 million, driven by strong demand in the U.S. and China, but also announced a wider net loss and negative adjusted EBITDA. Despite raising the low end of its full-year revenue guidance, shares fell over 5% due to investor concerns about profitability and increased operating costs. The company also launched new high-end products and is reorganizing into three customer-aligned business units to enhance growth and market penetration.
Cytek Biosciences Q2 Earnings: Revenue Up 6% to $48.1M | CTKB Stock News
Cytek Biosciences reported a 6% year-over-year revenue increase to $48.1 million in Q2 2026, driven by strong instrument sales in the U.S. and China and higher service revenue. Despite the revenue growth and improved gross margins, the company's net loss widened to $12.2 million, and adjusted EBITDA turned to a loss, largely due to increased operating expenses, including litigation-related costs. Cytek also launched new products, including the Cytek Borealis 7-laser flow cytometer, and raised its full-year 2026 revenue guidance.
Boston Partners (CTKB) discloses 7.64M-share beneficial stake in Cytek Biosciences
Boston Partners has reported a beneficial ownership of 7,635,145 shares of Cytek Biosciences, Inc. (CTKB) common stock, which represents a 5.91% stake in the company as of June 30, 2026. This disclosure was made via a Schedule 13G SEC filing, indicating that Boston Partners holds sole voting and dispositive power over these shares for the discretionary accounts of certain clients. The filing clarifies that no other person holds rights to dividends or sale proceeds for more than 5% of the outstanding common stock through Boston Partners' holdings.
Cytek Biosciences Inc (CTKB) Institutional Confidence
This article analyzes the institutional confidence score for Cytek Biosciences Inc (CTKB), which stands at 5.00, ranking 107th in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion is 65.16%, a decrease of 8.01% quarter-over-quarter. Bill Nygren (OAKMX) is the largest institutional shareholder with 1.80M shares, despite a significant reduction in holdings.
Cytek Biosciences Inc (CTKB) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Cytek Biosciences Inc (CTKB), detailing its price momentum, support and resistance levels, and various technical indicators. It highlights that the stock is currently trading between resistance at $4.75 and support at $4.21, suggesting a range-bound swing trading opportunity. The analysis also includes a breakdown of individual indicators and moving averages, concluding with a "Neutral" signal for the stock based on these technical factors.
Cytek Biosciences Inc (CTKB) Risk Assessment: Volatility, Financial Risk & Investment Risk
Cytek Biosciences Inc (CTKB) has a current risk assessment score of 4.63, placing it 98th out of 199 in the Healthcare Equipment & Supplies industry. The stock exhibits a beta value of 1.19, indicating higher volatility compared to the S&P 500. The assessment also details various risk metrics including VaR, maximum drawdown, volatility, and liquidity turnover rates.
Cytek Biosciences, Inc. Revenue Breakdown – TRADEGATE:8EQ
Cytek Biosciences, Inc. (8EQ) generated 171.55 million EUR in revenue last year, with its Full Spectrum Flow Cytometry Platform segment contributing the most at 122.80 million EUR. The United States was the largest regional contributor, accounting for 81.10 million EUR. This represents an increase from the previous year's total revenue of 148.05 million EUR.
CTKB|Cytek Biosciences Inc|Price:4.420|Chg%:-0.040
TradingKey provides a comprehensive stock analysis of Cytek Biosciences Inc (CTKB), highlighting its strong fundamentals, high growth potential, and fair valuation within the Healthcare Equipment & Supplies industry. The company's unique Full Spectrum Profiling (FSP) technology drives its cell analysis solutions. While institutional ownership is high and analysts rate it a "Buy," the stock price is noted to be trading sideways, making it suitable for range-bound swing trading despite an average market performance in the past month.
Cytek Biosciences Inc (CTKB) Cash Flow
This article provides a detailed overview of Cytek Biosciences Inc.'s (CTKB) cash flow statement, including operating, investing, and financing activities. It presents quarterly and annual financial figures, showing fluctuations and year-over-year changes in net income, capital expenditures, and free cash flow. The article also includes a FAQ section defining key cash flow terms and specific figures for CTKB, such as its operating cash flow of -6.84M in fiscal 2025.
Cytek Biosciences, Inc. Revenue Breakdown – FWB:8EQ
This article provides a revenue breakdown for Cytek Biosciences, Inc. (FWB:8EQ), detailing its top-performing segment and geographical contributions. Last year, the company generated €171.55 million in revenue, with the Full Spectrum Flow Cytometry Platform being the primary contributor and the United States accounting for the largest share of sales.
Cytek Biosciences Inc (CTKB) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Cytek Biosciences Inc (CTKB), listing its major institutional holders and their respective proportions. It also categorizes shareholders by type, such as Investment Advisors and Hedge Funds, and provides a historical overview of institutional shareholding changes across different quarters. Additionally, it highlights related ETFs that hold CTKB shares.
Cytek Biosciences Inc (CTKB) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Cytek Biosciences Inc (CTKB) focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years. The page displays current stock information including its price, market cap, and a "No Data" message for historical dividend and stock split records.
Cytek Biosciences Inc (CTKB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Cytek Biosciences Inc (CTKB) for Fiscal Year 2023. It categorizes revenue by business segments, namely "Biotechnology, pharmaceutical, distributor and CRO" and "Academia and government," and also by geographical regions including the United States, EMEA, APAC, and other areas. The data highlights that the biotechnology and pharmaceutical sector contributes the majority of revenue, with the United States leading in regional revenue generation.
CTKB|Cytek Biosciences Inc|Price:4.460|Chg%:-0.100
This article provides a comprehensive overview of Cytek Biosciences Inc (CTKB), including its current stock price, market performance, key financial figures, and analyst ratings. The company, which specializes in cell analysis solutions, is highlighted for its healthy fundamentals and significant growth potential, although its valuation is considered fairly valued. Analysts predominantly rate CTKB as a "Buy" with an attractive upside potential.
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?
This article analyzes Champions Oncology, Inc. (CSBR) and Cytek Biosciences, Inc. (CTKB), two life sciences companies, to determine which offers better long-term upside. It compares their stock performance, valuation, and factors driving their respective businesses, concluding that CSBR presents a more favorable entry point and stronger growth potential due to its specialized oncology platform and expanding data capabilities.
CTKB stock rises as Cytek BioSciences reports revenue and margin trends
Cytek BioSciences (CTKB) stock is being evaluated based on its reported revenue and margin trends, driven by its flow cytometry platform and recurring demand from its installed base. The article emphasizes that revenue, margin, and cash generation are key indicators, especially focusing on the installed base for future reagent and service sales, rather than unverified price movements.
Cytek Biosciences to report Q2 2026 results on August 5
Cytek Biosciences will report its second-quarter 2026 financial results after market close on August 5, 2026. This will be followed by a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results, business developments, and outlook. Investors can access the live audio webcast through the "Investors" section of the company's website.
Cytek Biosciences sets Q2 results call for 4:30 p.m. ET Aug. 5
Cytek Biosciences (Nasdaq: CTKB) announced it will report its second quarter 2026 financial results after market close on Wednesday, August 5, 2026. Management will host a webcast conference call at 1:30 p.m. Pacific / 4:30 p.m. Eastern to discuss results, business developments and outlook. The live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com.
Cytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026
Cytek Biosciences (NASDAQ: CTKB) announced it will release its second quarter 2026 financial results on August 5, 2026, after market close. The company will also host a conference call and webcast to discuss these results and provide a business update. A replay of the webcast will be available following the call for approximately 90 days.
Cytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026
Cytek Biosciences, Inc. (Nasdaq: CTKB) announced it will report its second-quarter 2026 financial results after market close on Wednesday, August 5, 2026. Following the release, company management will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss their financial results, business developments, and future outlook. The webcast will be accessible on the "Investors" section of CytekBio.com.
Cytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026
Cytek Biosciences, Inc. announced it will release its second-quarter 2026 financial results after market close on Wednesday, August 5, 2026. Following the release, the company will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results, business developments, and outlook. Details for accessing the webcast will be available on the "Investors" section of the company's website.
Cytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026
Cytek Biosciences, Inc. (Nasdaq: CTKB) announced it will report its second quarter 2026 financial results after market close on Wednesday, August 5, 2026. Management will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss these results, business developments, and future outlook. The live audio webcast will be accessible on the company's investor relations website.
Cytek Biosciences Opens Bellevue Innovation Center to Advance R&D and Customer Engagement
Cytek Biosciences has opened a new innovation center in Bellevue, Washington, relocating its Seattle-area operations to enhance research and development, collaboration, and customer engagement. The facility integrates R&D laboratories, training areas, and assembly operations, signifying Cytek's strategic investment in advancing high-dimensional cell analysis. This move aims to accelerate product development and reinforce the company's commitment to innovation within a technology-rich ecosystem.
Cytek Bio stock trades steadily as Q1 2026 growth and margin profile frame investor focus
Cytek Biosciences Inc. (CTKB) stock is trading steadily, reflecting a combination of revenue growth, improving margins, and an expanding installed base of cell analysis instruments. The company's Q1 2026 performance highlighted rising revenue driven by spectral flow cytometry instruments and associated reagents, alongside robust gross margins. Investors are focused on CTKB's path toward profitability, its growing installed base, and the increasing proportion of recurring revenue from consumables and services.
Cytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement
Cytek Biosciences has opened a new innovation center in Bellevue, Washington, relocating its previous Seattle-area operations. This facility is designed to support research and development, strengthen collaboration, and enhance customer engagement, featuring R&D laboratories, instrument service training areas, customer demonstration spaces, and assembly and testing operations. The center underscores Cytek’s commitment to advancing high-dimensional cell analysis and fostering continuous innovation in a region renowned for technology.
Cytek Biosciences (Nasdaq: CTKB) sets severance and consulting terms
Cytek Biosciences has detailed the separation terms for its former Chief Legal Officer and Corporate Secretary, Valerie Barnett, whose tenure ended on June 29, 2026. The agreement includes a one-time severance payment of $365,775.12 and COBRA premium coverage, with enhanced benefits if a Change in Control occurs within three months. Additionally, Ms. Barnett will provide transition support as a consultant at $1,000 per hour through August 31, 2026, during which her existing equity awards will continue to vest.
Cytek Biosciences Opens Bellevue Innovation Center to Advance R&D and Customer Engagement
Cytek Biosciences has opened a new innovation center in Bellevue, Washington, relocating its Seattle-area operations to enhance R&D, collaboration, and customer engagement. The facility, designed as a dedicated hub for innovation and technical excellence, will accelerate product development and support advanced technologies in cell analysis. This strategic investment aims to foster scientific progress and long-term growth within a region rich in technology companies.
Cytek's Valerie Barnett exits as Chief Legal Officer; consulting role agreed
Valerie Barnett's role as Chief Legal Officer and Corporate Secretary at Cytek terminated on June 29, 2026. She subsequently entered into a severance and consulting agreement in July 2026, which includes a one-time lump sum payment, COBRA premiums, and specific terms for her consulting services. The consulting agreement involves transition support compensated at $1,000/hr, up to 10 hours per week, through August 31, 2026, with previously granted equity awards continuing to vest.
Cytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement
Cytek Biosciences has announced the opening of a new innovation center in Bellevue, Washington, relocating its Seattle-area operations. This facility is designed to support research and development, strengthen collaboration, and enhance customer engagement with dedicated R&D laboratories, instrument service training, and customer demonstration areas. The strategic investment aims to advance high-dimensional cell analysis and accelerate product development within Cytek’s core Full Spectrum Profiling™ technology.
Cytek Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement
Cytek Biosciences has opened a new innovation center in Bellevue, Washington, relocating its Seattle-area operations. This facility is designed to enhance research and development, strengthen collaboration, and improve customer engagement with dedicated R&D labs, training spaces, and assembly operations. The investment underscores Cytek's commitment to advancing high-dimensional cell analysis and fostering innovation in a region known for technology companies.
Cytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement
Cytek Biosciences, a leader in spectral flow cytometry, has opened a new innovation center in Bellevue, Washington, relocating its Seattle-area operations. This facility is designed to enhance research and development, foster collaboration, improve customer engagement, and enable the development of next-generation cell analysis technologies. The investment reinforces Cytek's commitment to advancing scientific discovery and supporting long-term growth.
Cytek Biosciences Opens Innovation Center in Washington
Cytek Biosciences has announced the opening of its Innovation Center in Redmond, Washington. This new facility will serve as a hub for scientific collaboration, research, and product development in the field of cell analysis, particularly focusing on the company's full-spectrum flow cytometry technology. The center aims to foster partnerships and accelerate advancements in biological research and clinical applications.
BlackRock (NYSE: CTKB) holds 7.2% — 9.36M shares of Cytek Biosciences
BlackRock, Inc. has filed an amended Schedule 13G/A, disclosing a beneficial ownership of 9,356,551 shares in Cytek Biosciences, Inc. (CTKB), which represents 7.2% of the outstanding common stock as of June 30, 2026. The filing indicates BlackRock holds sole voting power over 9,228,737 shares and sole dispositive power over all 9,356,551 shares. This report provides a snapshot of BlackRock's significant passive investment in Cytek Biosciences, signed by a managing director on July 8, 2026.
Cytek Biosciences expands flow cytometry footprint amid growing immunology demand
Cytek Biosciences is expanding its presence in advanced flow cytometry, driven by increasing demand from immunology and cell therapy research. The company's systems and reagents aim to make high-parameter single-cell analysis more accessible, allowing researchers to study complex cell populations with high sensitivity and resolution. Cytek's technology focuses on generating richer datasets from each sample, supporting applications in oncology, vaccine research, and immune profiling.
CTKB - Cytek BioSciences Inc Latest SEC Filings
This article provides a detailed financial overview and snapshot of Cytek BioSciences Inc. (CTKB), including its recent stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It highlights various valuation ratios, sales and earnings growth rates, and stock statistics for investors.
If You Invested $1,000 in Cytek Biosciences, Inc. (CTKB)
This article analyzes the historical performance of investing $1,000 in Cytek Biosciences, Inc. (CTKB), a cell analysis solutions company. It details how such an investment would have fared over one year, highlighting a 35% return. The piece also provides an overview of Cytek Biosciences, its full spectrum profiling technology, products, customer base, geographic footprint, and public company status.
Cytek Biosciences explores growth paths as investors weigh long-term potential
Cytek Biosciences (CTKB, US23284C1053) is a life sciences company developing advanced instruments for cell analysis, particularly focusing on multi-parameter flow cytometry systems. The article highlights that with a thin news cycle, investor attention is on the company's long-term growth prospects, business model, and technology differentiation in the competitive life sciences tools market. Key areas of focus for investors include recurring revenue generation from instruments and consumables, R&D investment, operational efficiency, and a strong balance sheet to fund growth initiatives.
